Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Precision BioSciences, Inc. - Common Stock (NQ:DTIL)

6.970 +0.040 (+0.58%)
Streaming Delayed Price Updated: 2:00 PM EDT, Mar 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Precision BioSciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 3, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Inc (NASDAQ:DTIL) Stock Falls After Q3 2025 Earnings and Revenue Miss ↗
Precision BioSciences (DTIL) reported a major Q3 2025 earnings and revenue miss, causing shares to fall. Despite the financial setback, the company highlighted progress in its gene editing pipeline. 
Via Chartmill
News headline image
Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World Muscle Society
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status
From Precision BioSciences, Inc.
Via Business Wire
News headline image
DTIL Revenue Drops 99% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic
From Precision BioSciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.